# A Study to Compare the Number of Patients With Gastro-Oesophageal Reflux Disease (GORD) Achieving Heartburn and Regurgitation Symptom Resolution After Treatment With Either Rabeprazole Sodium 20mg, Esomeprazole 20mg or Esomeprazole 40mg

> **NCT00464308** · PHASE4 · COMPLETED · sponsor: **Janssen-Cilag Pty Ltd** · enrollment: 1392 (actual)

## Conditions studied

- Gastro-oesophageal Reflux

## Interventions

- **DRUG:** Esomeprazole
- **DRUG:** Rabeprazole
- **DRUG:** Esomeprazole

## Key facts

- **NCT ID:** NCT00464308
- **Lead sponsor:** Janssen-Cilag Pty Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-11
- **Primary completion:** 2008-05
- **Final completion:** 2008-05
- **Target enrollment:** 1392 (ACTUAL)
- **Last updated:** 2014-04-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00464308

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00464308, "A Study to Compare the Number of Patients With Gastro-Oesophageal Reflux Disease (GORD) Achieving Heartburn and Regurgitation Symptom Resolution After Treatment With Either Rabeprazole Sodium 20mg, Esomeprazole 20mg or Esomeprazole 40mg". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT00464308. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*